Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
100 hedge funds and large institutions have $194M invested in Adverum Biotechnologies in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 24 closing their positions.
1,604% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $187K
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
4% more funds holding
Funds holding: 96 → 100 (+4)
3.22% more ownership
Funds ownership: 55.65% → 58.88% (+3.2%)
3% less capital invested
Capital invested by funds: $201M → $194M (-$6.34M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.97M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.06M |
| 4 |
JP Morgan Chase
New York
|
+$3.34M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.1M |
| 2 |
Goldman Sachs
New York
|
-$3.68M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.21M |
| 4 |
NC
Nexthera Capital
New York
|
-$2.91M |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$2.63M |
ADVM Hedge Fund Activity: Q2 2018 in Review
100 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2018, worth a combined $194M — down 3.2% from $201M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ADVM positions and 24 closed out — a net gain of 5 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Millennium Management, cutting an estimated $9.1M.
- 100 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2018, up from 96 in Q1 2018.
- Funds reported $194M of Adverum Biotechnologies stock for Q2 2018, down 3.2% quarter-over-quarter.
- 29 funds opened new Adverum Biotechnologies positions in Q2 2018 and 24 closed out, a net change of +5 holders.
- The largest Adverum Biotechnologies buyer in Q2 2018 was BlackRock, an estimated $15.7M added.
- The largest Adverum Biotechnologies seller in Q2 2018 was Millennium Management, an estimated $9.1M sold.
Based on aggregated 13F filings for Q2 2018.